|
Malignant tumor of cervix
|
|
0.010 |
GeneticVariation
|
BEFREE |
A hundred HIV-infected women were examined for HPV detection and its genotypes, as well as the frequencies of the SNPs Arg72Pro and SNP309 and their associations with CC risk factors.
|
25181402 |
2015 |
|
Cervix carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
A hundred HIV-infected women were examined for HPV detection and its genotypes, as well as the frequencies of the SNPs Arg72Pro and SNP309 and their associations with CC risk factors.
|
25181402 |
2015 |
|
cervical cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
A hundred HIV-infected women were examined for HPV detection and its genotypes, as well as the frequencies of the SNPs Arg72Pro and SNP309 and their associations with CC risk factors.
|
25181402 |
2015 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Allele 399Gln (OR 1.57; 95% CI 1.05-2.35), Arg399Gln of gene XRCC1 heterozygous genotype (OR 2.77; 95% CI 1.60-4.80), the combination of Arg399Gln/Arg72Pro of genes XRCC1/TP53 heterozygous genotype (OR 3.98; 95% CI 1.57-10.09), Arg399Gln/T309G of genes XRCC1/MDM2 (OR 3.0; 95% CI 1.18-7.56), as well as Arg399Gln/Arg72Pro/T309G of genes XRCC1/TP53/MDM2 (OR 6.40; 95% CI 1.18-34.63) were associated with BC in Kyrgyz women.
|
29132330 |
2017 |
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
Allele 399Gln (OR 1.57; 95% CI 1.05-2.35), Arg399Gln of gene XRCC1 heterozygous genotype (OR 2.77; 95% CI 1.60-4.80), the combination of Arg399Gln/Arg72Pro of genes XRCC1/TP53 heterozygous genotype (OR 3.98; 95% CI 1.57-10.09), Arg399Gln/T309G of genes XRCC1/MDM2 (OR 3.0; 95% CI 1.18-7.56), as well as Arg399Gln/Arg72Pro/T309G of genes XRCC1/TP53/MDM2 (OR 6.40; 95% CI 1.18-34.63) were associated with BC in Kyrgyz women.
|
29132330 |
2017 |
|
Chronic Lymphocytic Leukemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
Although the p53 R72P SNPs and MDM2 SNP309 did not associate with any of the parameters studied, the BAX G125A SNPs was associated with a more advanced Binet stage at diagnosis, supporting a potential role for this variant in CLL disease progression.
|
17981213 |
2007 |
|
Solid Neoplasm
|
|
0.010 |
GeneticVariation
|
BEFREE |
Among the natural sequence variants of TP53, rs1042522 (R72P) modifies the risk for solid tumors.
|
19837266 |
2009 |
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
An increase in breast cancer-specific mortality was observed for carriers of the germline MDM2 SNP309 rare GG-genotype (range hazard ratios: 2-3) or TP53 R72P heterozygous GC-genotype (range hazard ratios: 1-2) compared to those having the common genotypes within subgroups of tumors displaying a "more aggressive phenotype" gene expression profile.
|
21667122 |
2011 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
An increase in breast cancer-specific mortality was observed for carriers of the germline MDM2 SNP309 rare GG-genotype (range hazard ratios: 2-3) or TP53 R72P heterozygous GC-genotype (range hazard ratios: 1-2) compared to those having the common genotypes within subgroups of tumors displaying a "more aggressive phenotype" gene expression profile.
|
21667122 |
2011 |
|
Endometrial Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer.
|
23624782 |
2013 |
|
Malignant neoplasm of endometrium
|
|
0.020 |
GeneticVariation
|
BEFREE |
Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer.
|
23624782 |
2013 |
|
Gastroesophageal reflux disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
Association of MDM2 T309G and p53 Arg72Pro polymorphisms and gastroesophageal reflux disease with survival in esophageal adenocarcinoma.
|
23735059 |
2013 |
|
Adenocarcinoma Of Esophagus
|
|
0.020 |
GeneticVariation
|
BEFREE |
Association of MDM2 T309G and p53 Arg72Pro polymorphisms and gastroesophageal reflux disease with survival in esophageal adenocarcinoma.
|
23735059 |
2013 |
|
Glioma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Association of p53 Arg72Pro and MDM2 SNP309 polymorphisms with glioma.
|
23096687 |
2012 |
|
HIV Infections
|
|
0.010 |
GeneticVariation
|
BEFREE |
Crude and adjusted associations involving each exposure (R72P and T309G SNPs, as well as 13 models of epistasis) and each outcome (HPV status, HPV oncogenic risk group and HIV infection) were assessed using logistic regression.
|
24586820 |
2014 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
ERCC1 Lys259Thr (rs735482), ERCC2 Lys751Gln (rs13181), ERCC5 His46His C>T (rs1047768), XRCC1 Arg399Gln (rs25487), TP53 Arg72Pro (rs1042522) and MDM2 309T>G (rs2279744) were analyzed on tumor DNA.
|
28351583 |
2017 |
|
Li-Fraumeni Syndrome
|
|
0.020 |
GeneticVariation
|
BEFREE |
Evaluation of TP53 Pro72Arg and MDM2 SNP285-SNP309 polymorphisms in an Italian cohort of LFS suggestive patients lacking identifiable TP53 germline mutations.
|
26956143 |
2016 |
|
Malignant Neoplasms
|
|
0.050 |
GeneticVariation
|
BEFREE |
Hence, this study explores the single and combined effects of cancer risk, age of onset and cancer type of three single nucleotide polymorphisms (SNPs)-TP53 Pro72Arg, MDM2 SNP285 and SNP309-already described as modifiers on TP53 mutation carriers but not properly investigated in LFS Suggestive patients.
|
26956143 |
2016 |
|
Primary malignant neoplasm
|
|
0.040 |
GeneticVariation
|
BEFREE |
Hence, this study explores the single and combined effects of cancer risk, age of onset and cancer type of three single nucleotide polymorphisms (SNPs)-TP53 Pro72Arg, MDM2 SNP285 and SNP309-already described as modifiers on TP53 mutation carriers but not properly investigated in LFS Suggestive patients.
|
26956143 |
2016 |
|
Squamous cell carcinoma of esophagus
|
|
0.010 |
GeneticVariation
|
BEFREE |
Here we showed that the risk of ESCC was elevated in subjects with any of the variant genot</span>ypes of PTEN rs2735343 and P53 Arg</span>72Pro polymorphisms, but not any genotype of MDM2 or PTEN rs701848.
|
22336889 |
2012 |
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here, we investigated the effect on breast cancer survival of germline variation in these genes in 925 Finnish breast cancer patients and further analyzed five single nucleotide polymorphisms (SNPs) in PRKAG2 (rs1029946, rs4726050, rs6464153, rs7789699) and PPP2R2B (rs10477313) for 10-year survival in breast cancer patients, interaction with TP53 R72P and MDM2-SNP309, outcome after specific adjuvant therapy and correlation to tumor characteristics in 4,701 invasive cases from four data sets.
|
23034890 |
2013 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here, we investigated the effect on breast cancer survival of germline variation in these genes in 925 Finnish breast cancer patients and further analyzed five single nucleotide polymorphisms (SNPs) in PRKAG2 (rs1029946, rs4726050, rs6464153, rs7789699) and PPP2R2B (rs10477313) for 10-year survival in breast cancer patients, interaction with TP53 R72P and MDM2-SNP309, outcome after specific adjuvant therapy and correlation to tumor characteristics in 4,701 invasive cases from four data sets.
|
23034890 |
2013 |
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
However, the results obtained from the combination of SNPs 344T>A of MDM2 and 72 Arg/Pro of p53, do not support the hypothesis of the prominent role of common p53 and MDM2 variations in the genetic mechanisms of chemotherapy resistance in breast cancer.
|
27569097 |
2016 |
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
However, the results obtained from the combination of SNPs 344T>A of MDM2 and 72 Arg/Pro of p53, do not support the hypothesis of the prominent role of common p53 and MDM2 variations in the genetic mechanisms of chemotherapy resistance in breast cancer.
|
27569097 |
2016 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome.
|
16258005 |
2006 |